NCT06253494 2026-04-09Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerNational Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting60 enrolled